TKNO Alpha Teknova, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1850902 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.4%
TTM net income YoY12.3%
TTM EPS YoY9.1%
Revenue 3-yr CAGR7.8%
Net income 3-yr CAGR—
Margins
Gross margin36.4%
Operating margin-32.7%
Net margin-34.8%
FCF margin-13.9%
EBITDA margin-20.1%
Returns
ROE-24.1%
ROA-15.8%
ROIC (approx.)-15.9%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets36.9%
Debt / equity0.22x
Current ratio3.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-10.3%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.70M | $12.19M | $11.08M | $9.98M | $10.45M | $10.29M | $9.79M | $9.27M |
| Cost of revenue | $7.88M | $7.30M | $7.29M | $6.74M | $7.25M | $6.30M | $6.79M | $7.14M |
| Gross profit | $4.83M | $4.88M | $3.78M | $3.24M | $3.21M | $3.98M | $3.01M | $2.13M |
| R&D expense | $581,000 | $554,000 | $609,000 | $522,000 | $542,000 | $581,000 | $552,000 | $594,000 |
| SG&A expense | $4.82M | $4.81M | $5.06M | $5.25M | $4.65M | $4.93M | $5.49M | $5.32M |
| Operating income | -$3.21M | -$2.89M | -$4.30M | -$4.61M | -$4.02M | -$3.39M | -$4.96M | -$5.63M |
| Pretax income | -$3.46M | -$3.14M | -$4.51M | -$4.82M | -$4.21M | -$3.55M | -$4.62M | -$5.76M |
| Income tax | $34,000 | $30,000 | $47,000 | -$62,000 | $79,000 | $19,000 | $22,000 | -$38,000 |
| Net income | -$3.49M | -$3.17M | -$4.55M | -$4.76M | -$4.29M | -$3.57M | -$4.64M | -$5.72M |
| EBITDA | -$1.91M | -$1.59M | -$2.72M | -$3.03M | -$2.72M | -$2.09M | -$3.38M | -$3.98M |
| EPS (basic) | -0.06 | -0.06 | -0.08 | — | -0.08 | -0.07 | -0.09 | — |
| EPS (diluted) | -0.06 | -0.06 | -0.08 | — | -0.08 | -0.07 | -0.09 | — |
| Weighted avg. shares (diluted) | 53.69M | 53.63M | 53.61M | — | 53.52M | 53.45M | 53.42M | — |
| Banking | ||||||||
| Net interest income | -$259,000 | -$252,000 | -$219,000 | -$211,000 | -$190,000 | -$165,000 | -$144,000 | -$129,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $6.63M | $6.00M | $4.31M | $5.91M | $3.20M | $3.28M | $3.38M | $3.71M |
| Short-term investments | $9.93M | $11.43M | $13.48M | $15.43M | $18.91M | $20.72M | $22.90M | $26.69M |
| Receivables | $5.82M | $5.41M | $5.67M | $4.62M | $5.13M | $5.14M | $5.62M | $4.31M |
| Inventory | $7.48M | $6.91M | $6.87M | $7.05M | $6.91M | $7.61M | $6.57M | $6.80M |
| Current assets | $31.80M | $30.82M | $31.67M | $34.51M | $36.56M | $38.06M | $39.73M | $42.78M |
| PP&E, net | $38.09M | $39.31M | $40.52M | $41.73M | $42.62M | $43.60M | $44.73M | $45.75M |
| Intangibles | $11.08M | $11.37M | $11.66M | $11.94M | $12.23M | $12.52M | $12.80M | $13.09M |
| Total assets | $94.68M | $95.88M | $98.66M | $103.58M | $107.62M | $110.49M | $113.99M | $118.77M |
| Current liabilities | $8.93M | $6.87M | $6.90M | $7.54M | $6.94M | $6.48M | $7.04M | $11.21M |
| Short-term debt | — | — | — | $0 | $0 | $0 | $0 | $4.04M |
| Long-term debt | $13.27M | $13.22M | $13.17M | $13.12M | $13.08M | $13.03M | $12.99M | $9.44M |
| Total debt | $13.27M | $13.22M | $13.17M | $13.12M | $13.08M | $13.03M | $12.99M | $13.49M |
| Total liabilities | $34.90M | $33.28M | $33.73M | $34.81M | $34.98M | $34.43M | $35.39M | $36.38M |
| Shareholders' equity | $59.78M | $62.60M | $64.92M | $68.78M | $72.65M | $76.06M | $78.61M | $82.39M |
| Net debt | $6.64M | $7.21M | $8.86M | $7.21M | $9.87M | $9.76M | $9.61M | $9.78M |
| Shares outstanding | 53.70M | 53.68M | 53.61M | 53.56M | 53.52M | 53.51M | 53.44M | 53.41M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.28M | -$471,000 | -$3.36M | -$462,000 | -$1.98M | -$2.10M | -$4.10M | -$936,000 |
| Capital expenditure | $120,000 | $125,000 | $221,000 | $348,000 | $387,000 | $207,000 | $206,000 | $567,000 |
| Free cash flow | -$1.40M | -$596,000 | -$3.58M | -$810,000 | -$2.37M | -$2.31M | -$4.31M | -$1.50M |
| Investing cash flow | $1.46M | $1.95M | $1.84M | $3.21M | $1.64M | $2.03M | $3.82M | -$1.41M |
| Financing cash flow | $449,000 | $224,000 | -$88,000 | -$37,000 | $268,000 | -$28,000 | -$52,000 | -$87,000 |
| Depreciation & amortization | $1.30M | $1.30M | $1.58M | $1.58M | $1.30M | $1.30M | $1.58M | $1.65M |
| Stock-based compensation | $612,000 | $622,000 | $695,000 | $777,000 | $850,000 | $950,000 | $950,000 | $766,000 |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.